These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 26601593

  • 21. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J, Rodríguez-Borjabad C, Ibarretxe D, Heras M, Amigo N, Feliu A, Masana L, Plana N, DECOPIN Group.
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [Abstract] [Full Text] [Related]

  • 22. IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.
    Scotti E, Calamai M, Goulbourne CN, Zhang L, Hong C, Lin RR, Choi J, Pilch PF, Fong LG, Zou P, Ting AY, Pavone FS, Young SG, Tontonoz P.
    Mol Cell Biol; 2013 Apr; 33(8):1503-14. PubMed ID: 23382078
    [Abstract] [Full Text] [Related]

  • 23. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
    Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJ, Tontonoz P, Zelcer N.
    J Biol Chem; 2010 Jun 25; 285(26):19720-6. PubMed ID: 20427281
    [Abstract] [Full Text] [Related]

  • 24. Regulation of intestinal LDLR by the LXR-IDOL axis.
    van Loon NM, van Wouw SAE, Ottenhoff R, Nelson JK, Kingma J, Scheij S, Moeton M, Zelcer N.
    Atherosclerosis; 2020 Dec 25; 315():1-9. PubMed ID: 33190106
    [Abstract] [Full Text] [Related]

  • 25. Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia.
    Yu Q, Zheng H, Zhang Y.
    Vascul Pharmacol; 2021 Oct 25; 140():106878. PubMed ID: 34015522
    [Abstract] [Full Text] [Related]

  • 26. The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans.
    Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AM, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P.
    J Clin Invest; 2011 Aug 25; 121(8):3062-71. PubMed ID: 21765216
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia.
    Chan ML, Shiu SW, Cheung CL, Yu-Hung Leung A, Tan KC.
    Endocr Connect; 2022 Jun 15; 11(6):. PubMed ID: 35560019
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.
    Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, Scotti E, Boyadjian R, Kim J, Chamberlain BT, Tangirala RK, Jung ME, Fong L, Lee R, Young SG, Temel RE, Tontonoz P.
    Cell Metab; 2014 Nov 04; 20(5):910-918. PubMed ID: 25440061
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Curcumin nicotinate increases LDL cholesterol uptake in hepatocytes through IDOL/LDL-R pathway regulation.
    Huang Y, Liu FY, Yang JT, Zhao Q, Zhu MQ, Wang J, Long SY, Tuo QH, Zhang CP, Lin LM, Liao DF.
    Eur J Pharmacol; 2024 Mar 05; 966():176352. PubMed ID: 38290567
    [Abstract] [Full Text] [Related]

  • 38. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor.
    Zhang L, Fairall L, Goult BT, Calkin AC, Hong C, Millard CJ, Tontonoz P, Schwabe JW.
    Genes Dev; 2011 Jun 15; 25(12):1262-74. PubMed ID: 21685362
    [Abstract] [Full Text] [Related]

  • 39. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
    Srivastava RAK.
    Cells; 2023 Jun 16; 12(12):. PubMed ID: 37371118
    [Abstract] [Full Text] [Related]

  • 40. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation.
    Pietiäinen V, Vassilev B, Blom T, Wang W, Nelson J, Bittman R, Bäck N, Zelcer N, Ikonen E.
    J Cell Sci; 2013 Sep 01; 126(Pt 17):3961-71. PubMed ID: 23813961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.